AG
RCKT icon

Aperio Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Aperio Group’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$239K Buy
+4,351
New +$159K ﹤0.01% 2260
2019
Q3 		– Sell
-1,307
Closed -$20K – 2658
2019
Q2 		$20K Buy
+1,307
New +$22.8K ﹤0.01% 2694

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Aperio Group's RCKT Position: Q4 2020 in Review

Aperio Group opened a new position in Rocket Pharmaceuticals (RCKT) in Q4 2020: 4,351 shares worth $239K. The stake represents ﹤0.01% of the portfolio and ranks #2260 among its holdings. This is a return to the name: Aperio Group previously reported a position in RCKT as recently as Q2 2019.

Aperio Group first reported a position in RCKT in Q2 2019 and has held it in 2 quarters since. 177 funds tracked by Wall St. Rank hold RCKT as of Q4 2020.

  • Aperio Group held 4,351 shares of Rocket Pharmaceuticals worth $239K as of Q4 2020.
  • Rocket Pharmaceuticals was a new Aperio Group position in Q4 2020.
  • Rocket Pharmaceuticals made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2260 holding.
  • Aperio Group first reported a position in Rocket Pharmaceuticals in Q2 2019 and has held it in 2 quarters since.
  • 177 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.